Clinical Trials

Tennessee Cancer Specialists

Lymphoma

CA209-812
Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma
Learn More

MOR208C204
Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND
Learn More

Pancreatic Cancer

EP-GF-301
A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Flourouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine
Learn More

Breast Cancer

C3441020
A phase 2, non-randomized, open label, single arm, multi-center study of Talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early triple-negative breast cancer
Learn More

Lung Cancer

MK3475-598 (Closed to enrollment)
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)
Learn More

EMR200647-001
A phase I, open label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with NSCLC
Learn More

ANAM-17-20
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Anamorelin HC1 for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLC
Learn More

Gastric Cancer

FPA144-004
A phase 3, randomized, double-blind, controlled study evaluating FPA144 and modified FOLFOX6 in patients with previously untreated advanced gastric and gastroesophageal cancer
Learn More

Multiple Cancers

EAY131
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Learn More

SERATRIALS 05035
Collection of blood for patients diagnosed or being treated for one or more health conditions or cancers of any kind.

StatCare Medical Group

Pulmonary Hypertension

TDE-HF-301
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) in Heart Failure with Preserved Ejection Fraction (HFpEF)
Learn More

TDE-HF-302
An Open-label Extension Study of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) Associated with Heart Failure with Preserved Ejection Fraction (HFpEF) – A Long-Term Follow-up to Study TDE-HF-301
Learn More

RIN-PH-201
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease
Learn More

RIN-PH-202
An Open-Label Extension study of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease
Learn More

APD811-301
A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH
Learn More

Pulmonary Atrial Hypertension

TDE-PH-401
ADAPT – A Patient Registry of the Real-world Use of Orenitram®
Learn More

NeuroGenesis

Dementia

992FD001 – (Closed to enrollment)
A Study to Model Rates of Change on Neuropsychological Test Measures in Subjects Diagnosed with Behavioral Variant Frontotemporal Dementia and Healthy Subjects
Learn More

Provision CARES Proton Therapy (Knoxville & Nashville)

Brain Cancer

NRG BN-001 – (Knoxville)
Randomized Phase II Trial Of Hypofractionated Dose-Escalated Photon IMRT OR Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant And Adjuvant Temozolomide In Patients With Newly Diagnosed Glioblastoma
Learn More

Prostate Cancer

PRO 1401 – (Knoxville & Nashville)
A Phase II Study of Hypofractionated Image Guided Proton Therapy for Low and Intermediate Risk Prostate Cancer
Learn More

PARTIQoL 11-497 – (Knoxville)
Prostate Advanced Radiation Technologies Investigating Quality of Life: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Learn More

13-217  PARTIQoL Registry – (Knoxville)
Prostate Advanced Radiation Technologies Investigating Quality of Life: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Learn More

COMPPARE – (Knoxville)
A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer
Learn More

Breast Cancer

RADCOMP – (Knoxville)
Pragmatic Phase Iii Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial
Learn More

Lung Cancer

RTOG 1308 – (Knoxville)
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
Learn More

Multiple Cancers

PRO 0425 – Proton Cancer Registry – (Knoxville & Nashville)
Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up
Learn More

Pediatric

PPCR 12-103 – (Knoxville)
Registry study for pediatric patients treated with proton radiation therapy in the United States
Learn More

Corporate Office

1400 Dowell Springs Blvd.,
Suite 350, Knoxville, TN 37909
Phone: (865) 934-2670
Contact Us
Privacy Practices

Research Office

1415 Old Weisgarber Road,
Suite 200, Knoxville, TN 37909
Phone: (865) 934-2670
Contact Us
Transparency in Coverage